For how we live.
The REACT study imaged people aged 18 to 70 with no known cardiovascular disease. Atherosclerosis was already present in some people in their twenties, and it was usually in the legs, not the heart.
PREMIUM tested prasugrel alone against aspirin plus prasugrel in 2,216 STEMI patients in Japan. Monotherapy failed to show noninferiority, and the confidence interval sat above one.
ABYSS and SMART-DECISION together cover 6,238 stable patients. Discontinuation cleared both noninferiority margins, though the authors say the primary endpoint's composition limits what it shows.
LIBREXIA-ACS enrolled 14,194 patients before stopping for futility. Milvexian did not reduce events, but intracranial and fatal bleeding were identical to placebo, which is the class's whole premise.
A meta-analysis of 45 cohorts found risk rising steadily with every 10 beats per minute. A study of 92,457 wearable users found one person's normal can differ from another's by 70 beats.
Pooling 11 cohort studies, researchers found a consistent cardiovascular signal in Asian and North American cohorts. European cohorts showed no elevated risk at all, a geographic split the analysis can't explain.
Nearly twice as many CPAP-treated patients saw their HFpEF-like markers improve at one year compared with those who went untreated — in a population sleep specialists have historically deprioritized for treatment.
Thirty-five people received VERVE-102 in a phase 1 trial. The edit is permanent, the follow-up is short, and the endpoint measured was cholesterol, not heart attacks.
PpgAge predicts chronological age from consumer wearable photoplethysmography and tracks disease. The same optical method has documented accuracy problems across skin tones.